Patents by Inventor Bruno Giethlen

Bruno Giethlen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • STYRLYQUINOLINES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTIC USES
    Publication number: 20110224242
    Abstract: The present disclosure concerns new substituted styrylquinolines, the process of their preparation and their therapeutic uses as integrase inhibitors and/or for the treatment and/or prevention of HIV.
    Type: Application
    Filed: July 23, 2009
    Publication date: September 15, 2011
    Applicant: BIOALLIANCE PHARMA
    Inventors: Bruno Giethlen, Mathieu Michaut, Claude Monneret, Emilienne Soma, Laurent Thibault, Camille Georges Wermuth
  • 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS
    Publication number: 20110201620
    Abstract: The present invention relates to the use of masitinib or a pharmaceutically acceptable salt thereof, and in particular of masitinib mesylate, for the preparation of a medicament for the treatment of GIST, to the use of this therapy for the treatment of GIST, and a method of treating mammals, including humans, suffering from GIST by administering to said mammal in need of such treatment an effective dose of masitinib, and in particular masitinib mesylate.
    Type: Application
    Filed: January 28, 2011
    Publication date: August 18, 2011
    Applicant: AB SCIENCE
    Inventors: Marco Ciufolini, Camille Wermuth, Bruno Giethlen, Alain Moussy, Jean-Pierre Kinet
  • Inhibitors of the Interaction Between MDM2 and P53
    Publication number: 20110053937
    Abstract: The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds of formula (I) wherein n, m, p, s, t, R1, R2, R3, R4, R5, R6, R7, X, Y, Q and Z have defined meanings.
    Type: Application
    Filed: November 3, 2010
    Publication date: March 3, 2011
    Inventors: Jean Fernand Armand Lacrampe, Christophe Meyer, Yannick Aimé Eddy Ligny, Imre Christian Francis Csoka, Luc Van Hijfte, Janine Arts, Bruno Schoentjes, Camille Georges Wermuth, Bruno Giethlen, Jean-Marie Contreras, Muriel Joubert
  • Inhibitors of the interaction between MDM2 and p53
    Patent number: 7834016
    Abstract: The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds of formula (I) wherein n, m, p, s, t, R1, R2, R3, R4, R5, R6, R7, X, Y, Q and Z have defined meanings.
    Type: Grant
    Filed: September 16, 2005
    Date of Patent: November 16, 2010
    Assignee: Janssen Pharmaceutica NV
    Inventors: Jean Fernand Armand Lacrampe, Christophe Meyer, Yannick Aimé Eddy Ligny, Imre Christian Francis Csoka, Luc Van Hijfte, Janine Arts, Bruno Schoentjes, Camille Georges Wermuth, Bruno Giethlen, Jean-Marie Contreras, Muriel Joubert
  • CYCLIC-ALKYLAMINE DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53
    Publication number: 20100168163
    Abstract: The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds of formula (I) wherein n, m, p, t, R1, R2, R3, R4, R5, R6, R7, Q, Y and Z have defined meanings.
    Type: Application
    Filed: March 19, 2007
    Publication date: July 1, 2010
    Inventors: Jean Fernand Armand Lacrampe, Christophe Meyer, Bruno Schoentjes, Alain Philippe Poncelet, Camille Georges Wermuth, Bruno Giethlen, Jean-Marie Contreras, Muriel Joubert, Luc Van Hijfte
  • 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
    Patent number: 7718676
    Abstract: The present invention relates to novel compounds selected from 2-aminoaryloxazoles of formula I that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective c-kit, bcr-abl, FGFR3 and/or Flt-3 inhibitors.
    Type: Grant
    Filed: October 22, 2004
    Date of Patent: May 18, 2010
    Assignees: AB Science, Centre National de la Recherche Scientifique (CNRS), Institut Curie
    Inventors: Alain Moussy, Camille Wermuth, David Grierson, Abdellah Benjahad, Martine Croisy, Marco Ciufolini, Bruno Giethlen
  • 7-substituted 3-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials
    Patent number: 7713965
    Abstract: A subject of the invention is the compounds of formula (I): in which either R1 represents H, OH, NH2, —(CH2)m—NRaRb(m=0.1 or 2), Ra and Rb represent H, linear, branched or cyclic (C1-C6) alkyl, (C3-C6) cycloalkyl-(C3-C6)— alkyl, Rc, S(O)2Rc, C(O)Rc, S(O)2Rd or C(O)Rd; or Ra and Rb with N form an Rc radical; Rc represents a saturated, unsaturated or 5- or 6-members aromatic ring, containing 1 to 4 heteroatoms chosen from N, O and S, optionally substituted; Rd represents a linear, branched or cyclic (C1-C6) alkyl, optionally substituted by 1 to 4 halogens; or R1 represents Rc or CHReRc or CHReRd; Re represents H, OH, NH2, NH—(C1-C6)-alk or N-(C1-C6)-alk2, or NH—(C1-C7)-acyl or NHRc; R2 represents H, (CH2)m—NRaRb, Rc, CHReRc or CHReRd, and R?2 represents H.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: May 11, 2010
    Assignee: Vetoquinol SA
    Inventors: Paola Ciapetti, Florence Chery-Mozziconacci, Camille G. Wermuth, Françoise Leblanc, Marc Schneider, Sandrine Ropp, Christophe Morice, Bruno Giethlen
  • 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors
    Publication number: 20100113471
    Abstract: The present invention relates to novel compounds selected from 2-aminoaryloxazoles that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic and degenerative disorders. More particularly, these compounds are potent and selective c-kit, bcr-abl, FGFR3 and/or Flt-3 inhibitors.
    Type: Application
    Filed: January 11, 2010
    Publication date: May 6, 2010
    Inventors: Alain Moussy, Camille Wermuth, David Grierson, Abdellah Benjahad, Martine Croisy, Marco Ciufolini, Bruno Giethlen
  • NOVEL 9-SUBSTITUTED-5-CARBOXY-OXADIAZINO-QUINOLONE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ANTI-BACTERIALS
    Publication number: 20100009980
    Abstract: A subject of the invention is the compounds of formula (I): wherein R1, R2, R3, R?3, R4, R?4, R5, R6 and R7 are as described in the application, in the form of enantiomers or mixtures, as well as their salts with acids and bases, their preparation and their application as anti-bacterials, in both human and veterinary medicine.
    Type: Application
    Filed: June 23, 2009
    Publication date: January 14, 2010
    Applicant: Vetoquinol SA
    Inventors: Sandrine Ropp, Christophe Morice, Bruno Giethlen, Paola Ciapetti, Florence Chery-Mozziconacci, Camille G. Wermuth, Francoise Leblanc, Marc Schneider
  • N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR
    Publication number: 20090306110
    Abstract: The present invention provides compounds of formula (I), which are antagonists of the 5-HT6 receptor.
    Type: Application
    Filed: July 16, 2009
    Publication date: December 10, 2009
    Inventors: Zhaogen Chen, Michael Philip Cohen, Matthew Joseph Fisher, Bruno Giethlen, James Ronald Gillig, Jefferson Ray McCowan, Shawn Christopher Miller, John Mehnert Schaus
  • NOVEL 7-SUBSTITUTED 3-CARBOXY-OXADIAZINO-QUINOLONE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ANTI-BACTERIALS
    Publication number: 20090221565
    Abstract: A subject of the invention is the compounds of formula (I): in which either R1 represents H, OH, NH2, —(CH2)m—NRaRb(m=0.
    Type: Application
    Filed: February 27, 2009
    Publication date: September 3, 2009
    Applicant: Vetoquinol SA
    Inventors: Sandrine Ropp, Christophe Morice, Bruno Giethlen, Paola Ciapetti, Florence Chery-Mozziconacci, Camille G. Wermuth, Francoise Leblanc, Marc Schneider
  • Inhibitors of the Interaction Between Mdm2 and P53
    Publication number: 20080039472
    Abstract: The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds of formula (I) wherein n, m, p, s, t, R1, R2, R3, R4, R5, R6, R7, X, Y, Q and Z have defined meanings.
    Type: Application
    Filed: September 16, 2005
    Publication date: February 14, 2008
    Applicant: JANSSEN PHARMACEUTICA N.V.
    Inventors: Jean Lacrampe, Christophe Meyer, Yannick Ligny, Imre Csoka, Luc Van Hijfte, Janine Arts, Bruno Schoentjes, Camille Wermuth, Bruno Giethlen, Jean-Marie Contreras, Muriel Joubert
  • 2-(3-Substituted-Aryl) Amino-4-Aryl-Thiazoles As Tyrosine Kinase Inhibitors
    Publication number: 20080039466
    Abstract: The present invention relates to novel compounds selected from 2-(3substitutedaryl)amino-4-aryl-thiazoles that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective c-kit inhibitors.
    Type: Application
    Filed: January 28, 2005
    Publication date: February 14, 2008
    Inventors: Alain Moussy, Marco Ciufolini, Camille Wermuth, Bruno Giethlen
  • 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors
    Publication number: 20070142390
    Abstract: The present invention relates to novel compounds selected from 2-aminoaryloxazoles of formula I that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective c-kit, bcr-abl, FGFR3 and/or Flt-3 inhibitors.
    Type: Application
    Filed: October 22, 2004
    Publication date: June 21, 2007
    Inventors: Alain Moussy, Camille Wermuth, David Grierson, Abdellah Benjahad, Martine Croisy, Marco Ciufolini, Bruno Giethlen
  • N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR
    Publication number: 20070099909
    Abstract: The present invention provides compounds of formula (I), which are antagonists of the 5-HT6 receptor.
    Type: Application
    Filed: December 11, 2006
    Publication date: May 3, 2007
    Inventors: Zhaogen Chen, Michael Cohen, Matthew Fisher, Bruno Giethlen, James Gillig, Jefferson McCowan, Shawn Miller, John Schaus
  • N-(2-Arylethyl) benzylamines as antagonists of the 5-HTreceptor
    Patent number: 7157488
    Abstract: The present invention provides compounds of formula I pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are antagonists of the 5-HT6 receptor. The present invention further provides a method of treating disorders associated with 5-HT6 receptors, including schizophrenia, anxiety, Alzheimer's disease, and cognitive disorders selected from the group consisting of age-related cognitive decline, mild cognitive impairment, and dementia, comprising: administering to a patient in need thereof an effective amount of a compound of formula I.
    Type: Grant
    Filed: March 15, 2002
    Date of Patent: January 2, 2007
    Assignee: Eli Lilly and Company
    Inventors: Zhaogen Chen, Michael Philip Cohen, Matthew Joseph Fisher, Bruno Giethlen, James Ronald Gillig, Jefferson Ray McCowan, Shawn Christopher Miller, John Mehnert Schaus
  • N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor
    Publication number: 20060009511
    Abstract: The present invention provides compounds of formula (I), which are antagonists of the 5-HT6 receptor.
    Type: Application
    Filed: March 15, 2002
    Publication date: January 12, 2006
    Inventors: Zhaogen Chen, Michael Cohen, Matthew Fisher, Bruno Giethlen, James Gillig, Jefferson McCowan, Shawn Miller, John Schaus
  • N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor
    Publication number: 20040132800
    Abstract: The present invention provides compounds of formula (I), which are antagonists of the 5-HT6 receptor.
    Type: Application
    Filed: February 27, 2004
    Publication date: July 8, 2004
    Inventors: Zhaogen Chen, Michael Philip Cohen, Matthew Joseph Fisher, Bruno Giethlen, James Ronald Gillig, Jefferson Ray McCowan, Shawn Christopher Miller, John Mehnert Schaus